Clinical prediction based on HPV DNA testing by hybrid capture 2 (HC2) in combination with liquid-based cytology (LBC)

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 903-907

  Junyangdikul, Pairoj ^a   Tanchotsrinon, Watcharaporn ^b   Chansaenroj, Jira ^c   Nilyaimit, Pornjarim ^c   Lursinsap, Chidchanok ^b   Poovorawan, Yong ^c  

^a Bangkok Hospital Medical Center   (Thailand)

^b Faculty of Science   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

HSIL; Human papillomavirus; Hybrid capture 2; LSIL; Thailand

Indexed keywords

VIRUS DNA;

ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; METHODOLOGY; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84877679229     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.903     Document Type: Article

References (32)

1. ASCUS-LSIL Triage Study (ALTS) Group (2003). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol, 188, 1383-92.
2. Belinson JL, Wu R, Belinson SE, et al (2011). A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. Am J Clin Pathol, 135, 790-5.
3. Bhatla N, Moda N (2009). The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J Med Res, 130, 261-5.
4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
5. Bozzetti M, Nonnenmacher B, Mielzinska II, et al (2001). Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Ann Epidemiol, 10, 466.
6. Cañadas MP, Cirigliano V, Darwich L, et al (2012). Comparison of the f-HPV typing™ and Hybrid Capture II® assays for detection of high-risk HPV genotypes in cervical samples. J Virol Methods, 183, 14-8.
7. Carestiato FN, Silva KC, Dimetz T, et al (2006). Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Br J Infectious Diseases, 10, 331-6.
8. Castle PE, Schiffman M, Burk RD, et al (2002). Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev, 11, 1394-9.
9. Castle PE, Solomon D, Wheeler CM, et al (2008). Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol, 46, 2595-604.
10. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL (2006). Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine, 24, 26-34.
11. Comar M, Iannacone MR, Casalicchio G, et al (2012). Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol, 50, 4041-6.
12. Federschneider JM, Yuan L, Brodsky J, et al (2004). The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am J Obstet Gynecol, 191, 757-61.
13. Forslund O, Antonsson A, Edlund K, et al (2002). Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol, 66, 535-41.
14. Giorgi RP, Bisanzi S, Paganini I, et al (2010). Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infectious Diseases, 10, 214.
15. Iftner T, Villa LL (2003). Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr, 31, 80-8.
16. Kurian EM, Caporelli ML, Baker S, et al (2011). Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. Am J Clin Pathol, 136, 808-16.
17. Lee GY, Kim SM, Rim SY, et al (2005). Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions. Int J Gynecol Cancer, 15, 81-7.
18. Menzo S, Ciavattini A, Bagnarelli P, et al (2008). Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol, 8, 112.
19. Molijn A, Kleter B, Quint W, van Doorn LJ (2005). Molecular diagnosis of human papillomavirus (HPV) infections. J Clinical Virology, 32, 43-51.
20. Munoz N, Bosch FX, de Sanjosé S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
21. Nanda K, McCrory DC, Myers ER, et al (2000). Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Annals of Internal Med, 132, 810-9.
22. Nishino HT, Tambouret RH, Wilbur DC (2011). Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. Cancer Cytopathol, 119, 219-27.
23. Núñez-Troconis J, Delgado M, González J, et al (2009). Human papillomavirus false positive cytological diagnosis in low grade squamous intraepithelial lesion. Invest Clin, 50, 447-54.
24. Ogilvie GS, Cook DA, Taylor DL, et al (2013). Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. Vaccine, 31, 1129-33.
25. Peyton CL, Schiffman M, Lörincz AT, et al (1998).Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol, 36, 3248-54.
26. Ronco G, Cuzick J, Segnan N, et al (2007). HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer, 43, 476-80.
27. Schiffman M, Castle PE (2003). Human papillomavirus: Epidemiology and public health. Arch Pathol Lab Med, 127, 930-4.
28. Seme K, Fujs K, Kocjan BJ, Poljak M (2006). Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods, 134, 252-6.
29. Terry G, Ho L, Londesborough P, et al (2001). Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol, 65, 155-62.
30. Thrall MJ, Smith DA, Mody DR (2009). Women ≥30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women? Diagn Cytopathol, 38, 407-12.
31. Tsao KC, Huang CG, Kuo YB, et al (2010). Prevalence of human papillomavirus genotypes in northern Taiwanese women. J Med Virol, 82, 1739-45.
32. Tsiodras S, Georgoulakis J, Chranioti A, et al (2010). Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer, 10, 53.